Invir.IO® based oncolytic virus TG6050, is armed with IL-12 and an anti-CTLA4 antibody. A Phase I trial (Delivir) recently started enrolling patients with advanced non-small cell lung cancer (NSCLC)
Strasbourg, France, April 17, 2023, 7:30 a.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, presented promising preclinical data on its novel oncolytic virus TG6050, at the American Association for Cancer Research (AACR) Annual Meeting, April 14-19, 2023.
These data demonstrate the ability of TG6050 to induce strong antitumor responses through the production of IL-12 and anti-CTLA4 antibody in the tumor and the induction of innate and adaptive immune responses.
TG6050 is a clinical-stage oncolytic virus that has been engineered to encode human IL-12 and a full length anti-CTLA4 antibody. It is derived from the Invir.IO® platform and its patented
VVCOPTK-RR- viral vector which was shown to be well tolerated in humans and to replicate and express payloads in tumor tissues.
.../...
0 commentaire
Vous devez être membre pour ajouter un commentaire.
Vous êtes déjà membre ? Connectez-vous
Pas encore membre ? Devenez membre gratuitement
Signaler le commentaire
Fermer